TIP_link_300x300.jpg
Child Resistant Closures Market Size to Reach $3.44 Bn by 2028 | The Insight Partners
November 08, 2023 08:54 ET | The Insight Partners
Pune, India, Nov. 08, 2023 (GLOBE NEWSWIRE) -- According to our new research study, titled "Child Resistant Closures Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Material,...
Immuneering-logo (1).png
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023 16:05 ET | Immuneering Corporation
- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First...
Immuneering-logo (1).png
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
March 05, 2023 18:30 ET | Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...
Immuneering-logo (1).png
Immuneering Announces Participation in March Investor Conferences
February 28, 2023 08:00 ET | Immuneering Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Sai.png
SAI.TECH Announces Sponsorship and Presence on the 2022 Cryptocurrency Research Conference
September 19, 2022 08:00 ET | SAI.TECH Global Corporation
SINGAPORE, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Today, SAI.TECH Global Corporation ("SAI.TECH" OR "SAI", NASDAQ: SAI), a global energy-saving bitcoin mining operator and a clean-tech company that...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
June 13, 2022 07:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized...
logo.png
Verano Founder and Chief Executive Officer George Archos and Chief Operating Officer Darren Weiss Share Celebratory Comments on New Jersey Cannabis Regulatory Commission’s Approval of Personal Use Cannabis Sales
April 11, 2022 16:21 ET | Verano Holdings Corp.
CHICAGO, April 11, 2022 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today shared executive commentary...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 21, 2022 08:00 ET | Compass Therapeutics
Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...
Biosplice logo_final RGB 300 dpi_white background.png
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology
November 17, 2021 09:15 ET | Biosplice Therapeutics, Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
October 29, 2020 16:36 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended...